Market Overview:
The global drugs for asthma and COPD market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of asthma and COPD, rising awareness about these diseases, and technological advancements in drug delivery devices. In addition, the growing demand for generic drugs is also contributing to the growth of this market. The global drugs for asthma and COPD market can be segmented on the basis of type into generic drugs and patented drugs. The generic drug segment is expected to grow at a higher CAGR than the patented drug segment during the forecast period from 2018 to 2030. This can be attributed to factors such as lower prices and easy availability of these drugs compared with patented ones. On the basis of application, this market can be divided into asthma and COPD.
Product Definition:
Drugs for Asthma and COPD are medications used to treat the symptoms of asthma and chronic obstructive pulmonary disease (COPD). They work by opening up the airways in the lungs, making it easier to breathe.
Generic Drugs:
The generic drugs market is expected to grow at a lucrative rate during the forecast period. The growth of this market is attributed to factors such as increasing healthcare costs, rising aging population, and growing awareness about cost-effective treatment options.
Furthermore, patent expiration of branded drugs coupled with increasing R&D activities by companies for developing generics are some other drivers of this market.
Patented Drugs:
Patented drugs are a special category of pharmaceutical products that enjoy legal protection from the moment they are patented until the expiry date specified by law. The patent gives the right to manufacture, use and sell the product as well as to prepare new formulations of existing products.
Patented drug refers to any pharmaceutical product whose development has been patented by an individual or a company.
Application Insights:
Asthma held the largest share of 77.4% in 2017 in terms of revenue as well as volume. Increasing awareness about asthma and its symptoms, growing prevalence, and rising number of hospitalizations are some of the major factors contributing to its large share. On the other hand, COPD is estimated to be the fastest-growing segment during forecast years owing to increasing cases worldwide due to aging population and pollution.
The introduction of new drugs with different mechanisms of action is one among several factors that have driven research in recent years regarding new therapeutic areas for treating COPD patients effectively without having any adverse effects on their health like heart diseases or blood pressure problems which are usually observed when a patient suffers from severe COPD. Thus, there is an urgent need for developing effective therapies for treating this condition which can be done through various avenues such as gene therapy or stem cell therapy etc.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of asthma are some factors responsible for its growth. According to the National Institute for Health and Care Excellence (NICE), around 1 million adults in U.K., have asthma that requires them to take an inhaled bronchodilator at least once a week or twice a day on average.
Growth Factors:
- Increasing prevalence of asthma and COPD
- Growing awareness about the available treatment options for asthma and COPD
- Rising demand for better-quality drugs to treat asthma and COPD
- Technological advancements in the field of drug development for asthma and COPD 5. Availability of government funding for research on drugs for asthma and COPD
Scope Of The Report
Report Attributes
Report Details
Report Title
Drugs for Asthma and COPD Market Research Report
By Type
Generic Drugs, Patented Drugs
By Application
Asthma, COPD
By Companies
GSK, Novartis, Merck, Abbott, Boehringer Ingelheim, AstraZeneca, Roche, Teva, Vectura, Pfizer, GSK, Allergan, Cipla, Akorn, Apotex
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
205
Number of Tables & Figures
144
Customization Available
Yes, the report can be customized as per your need.
Global Drugs for Asthma and COPD Market Report Segments:
The global Drugs for Asthma and COPD market is segmented on the basis of:
Types
Generic Drugs, Patented Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Asthma, COPD
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Novartis
- Merck
- Abbott
- Boehringer Ingelheim
- AstraZeneca
- Roche
- Teva
- Vectura
- Pfizer
- GSK
- Allergan
- Cipla
- Akorn
- Apotex
Highlights of The Drugs for Asthma and COPD Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Generic Drugs
- Patented Drugs
- By Application:
- Asthma
- COPD
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drugs for Asthma and COPD Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Drugs for asthma and COPD are medications used to treat the symptoms of these conditions. These drugs can help improve airflow in the lungs, reduce inflammation, and relieve pain.
Some of the major players in the drugs for asthma and copd market are GSK, Novartis, Merck, Abbott, Boehringer Ingelheim, AstraZeneca, Roche, Teva, Vectura, Pfizer, GSK, Allergan, Cipla, Akorn, Apotex.
The drugs for asthma and copd market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Drugs for Asthma and COPD Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Drugs for Asthma and COPD Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Drugs for Asthma and COPD Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Drugs for Asthma and COPD Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Drugs for Asthma and COPD Market Size & Forecast, 2020-2028
4.5.1 Drugs for Asthma and COPD Market Size and Y-o-Y Growth
4.5.2 Drugs for Asthma and COPD Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Generic Drugs
5.2.2 Patented Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Asthma
6.2.2 COPD
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Drugs for Asthma and COPD Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Drugs for Asthma and COPD Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Generic Drugs
9.6.2 Patented Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Asthma
9.10.2 COPD
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Generic Drugs
10.6.2 Patented Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Asthma
10.10.2 COPD
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Generic Drugs
11.6.2 Patented Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Asthma
11.10.2 COPD
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Generic Drugs
12.6.2 Patented Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Asthma
12.10.2 COPD
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Generic Drugs
13.6.2 Patented Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Asthma
13.10.2 COPD
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Drugs for Asthma and COPD Market: Competitive Dashboard
14.2 Global Drugs for Asthma and COPD Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GSK
14.3.2 Novartis
14.3.3 Merck
14.3.4 Abbott
14.3.5 Boehringer Ingelheim
14.3.6 AstraZeneca
14.3.7 Roche
14.3.8 Teva
14.3.9 Vectura
14.3.10 Pfizer
14.3.11 GSK
14.3.12 Allergan
14.3.13 Cipla
14.3.14 Akorn
14.3.15 Apotex
